VYGR Stock Analysis: Buy, Sell, or Hold?
VYGR - Voyager Therapeutics, Inc. Common Stock
$3.00
-0.03 (-0.99%)
▼
5d:
-2.91%
30d:
-20.63%
90d:
-20.21%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When VYGR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VYGR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VYGR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VYGR is currently trading at $3.00, which is considered oversold relative to its 30-day fair value range of $3.03 to $3.58.
Technical Outlook: Technically, VYGR is in a downtrend. The price is currently testing key support at $2.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VYGR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.89 (+396.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VYGR is in a downtrend. The price is currently testing key support at $2.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VYGR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.89 (+396.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.03 -
$3.58
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 396.3% below Wall St target ($14.89)
Trading Range Analysis
30-Day Trading Range
$3.03 -
$3.58
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.69
(22.8%)
Support & Resistance Levels
Support Level
$2.94
Resistance Level
$3.28
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.92
Wall Street Target
$14.89
(+396.3%)
Revenue Growth (YoY)
-59.9%
Share & Embed Analysis
Last updated: August 04, 2026 7:29 AM ET
Data refreshes hourly during market hours. Next update: 8:29 AM
Data refreshes hourly during market hours. Next update: 8:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYGR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Alfred Sandrock
SELL
11511 shares
2026-04-02
Alfred Sandrock
SELL
14197 shares
2026-02-24
Nathan D Jorgensen
SELL
4668 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 54 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 61 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 BUY |
